Literature DB >> 26707323

Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid Organ Transplantation.

L Yessayan1, A Shafiq2, E Peterson3, K Wells3, Y Hu3, L K Williams4, D Lanfear5.   

Abstract

BACKGROUND: Calcineurin-inhibitor (CNI)-induced nephrotoxicity frequently complicates transplantation. African-Americans are at a greater risk of renal failure than the general population. We investigated whether race was an effect modifier of the relationship between CNI exposure and kidney function after nonrenal solid organ transplantation.
METHODS: This is a retrospective cohort study of 1609 patients who underwent initial nonrenal solid organ transplantation between January 2000 and June 2012. A central repository administrative database was queried electronically for demographics, comorbidities, and serial levels of tacrolimus, cyclosporine, and serum creatinine. Predictors of interest were total drug exposure of tacrolimus and cyclosporine (area under the concentration-time curve) and self-reported race. The outcome of interest was cumulative change in estimated glomerular filtration rate (GFR).
RESULTS: There were 1109 patients treated with tacrolimus (271 African-Americans) and 500 patients treated with cyclosporine (113 African Americans). A decline in GFR over time was seen with total tacrolimus exposure (-1.3 mL/min/1.73 m(2) for every 5 ng/mL·year increase in tacrolimus) and total cyclosporine exposure (-1.1 mL/min/1.73 m(2) for every 50 ng/mL·year increase in cyclosporine). However, total CNI exposure effect on estimated GFR changes did not vary by race (P interaction was 0.9 for tacrolimus and 0.6 for cyclosporine).
CONCLUSIONS: Total CNI exposure is associated with worsening kidney function among patients with nonrenal solid organ transplantation. However, African-American patients are not more vulnerable to chronic CNI-induced nephrotoxicity when compared to white patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26707323      PMCID: PMC4819428          DOI: 10.1016/j.transproceed.2015.10.052

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  50 in total

1.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.

Authors:  Dennis A Hesselink; Ron H N van Schaik; Ilse P van der Heiden; Marloes van der Werf; Peter J H Smak Gregoor; Jan Lindemans; Willem Weimar; Teun van Gelder
Journal:  Clin Pharmacol Ther       Date:  2003-09       Impact factor: 6.875

2.  Outcome of liver transplantation in adult recipients: influence of neighborhood income, education, and insurance.

Authors:  Hwan Young Yoo; Paul J Thuluvath
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

3.  Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression.

Authors:  Mandeep R Mehra; Patricia A Uber; Robert L Scott; Myung H Park
Journal:  Transplantation       Date:  2002-12-15       Impact factor: 4.939

4.  Influence of race in heart failure and cardiac transplantation: mortality differences are eliminated by specialized, comprehensive care.

Authors:  Salpy V Pamboukian; Maria Rosa Costanzo; Peter Meyer; Linda Bartlett; Mary McLeod; Alain Heroux
Journal:  J Card Fail       Date:  2003-04       Impact factor: 5.712

Review 5.  Cyclosporine nephrotoxicity.

Authors:  Emmanuel A Burdmann; Takeshi F Andoh; Luis Yu; William M Bennett
Journal:  Semin Nephrol       Date:  2003-09       Impact factor: 5.299

Review 6.  Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.

Authors:  Roberto Marcén
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

7.  Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.

Authors:  Dany Anglicheau; Céline Verstuyft; Pierre Laurent-Puig; Laurent Becquemont; Marie-Hélène Schlageter; Bruno Cassinat; Philippe Beaune; Christophe Legendre; Eric Thervet
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

Review 8.  Tacrolimus-associated hemolytic uremic syndrome: a case analysis.

Authors:  Chih-Ching Lin; Kuang-Liang King; Yu-Wen Chao; An Han Yang; Chao-Fu Chang; Wu-Chang Yang
Journal:  J Nephrol       Date:  2003 Jul-Aug       Impact factor: 3.902

9.  Chronic renal failure after transplantation of a nonrenal organ.

Authors:  Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

Review 10.  Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology?

Authors:  K Morozumi; A Takeda; K Uchida; M J Mihatsch
Journal:  Transplant Proc       Date:  2004-03       Impact factor: 1.066

View more
  3 in total

1.  Black Race Is Associated With Higher Rates of Early-Onset End-Stage Renal Disease and Increased Mortality Following Liver Transplantation.

Authors:  Meagan Alvarado; Douglas E Schaubel; K Rajender Reddy; Therese Bittermann
Journal:  Liver Transpl       Date:  2021-04-21       Impact factor: 6.112

2.  Current Status of Adverse Event Profile of Cyclosporine in Kidney, Stem Cell, and Heart Transplantations Using the Japanese Pharmacovigilance Database.

Authors:  Iku Niinomi; Saki Oyama; Ayaka Inada; Tomohito Wakabayashi; Tatsuya Iida; Hiroko Kambara; Mayako Uchida; Yukako Sano; Keiko Hosohata
Journal:  Cureus       Date:  2022-09-20

3.  Increased Incidence of Chronic Kidney Injury in African Americans Following Cardiac Transplantation.

Authors:  Joseph Bayne; Michael Francke; Elaine Ma; Geoffrey A Rubin; Uma Mahesh R Avula; Haajra Baksh; Raymond Givens; Elaine Y Wan
Journal:  J Racial Ethn Health Disparities       Date:  2020-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.